en
Locations
  • Custom development & Manufacturing
    Custom development & Manufacturing
    • Custom development & Manufacturing
    • Early Phase API Development
    • Late Phase API Development
    • Custom API manufacturing Services
    • Special Technologies & Capabilities
      • Special Technologies & Capabilities
      • Reactions Technologies
      • Controlled Substance API Manufacturing
      • Biocatalysis Contact Manufacturing
      • High-Potency APIs (HPAPIs)
    • SEQENS' LAB
      • SEQENS' LAB
      • About Seqens'Lab
      • Seqens’Lab 360° TOUR
  • Proprietary APIs
    Proprietary APIs
    • Proprietary APIs
    • APIs Development & Production
    • APIs Solid-Form Customization
    • Drug substance Regulatory Affairs and Quality Assurance
    • Product Catalog
  • Consumer Health APIs
  • Proprietary API Intermediates
    Proprietary API Intermediates
    • Proprietary API Intermediates
    • Registered API Intermediates & Raw Materials
    • Pre-GMP API Intermediates / Catalog
  • Drug Delivery & Materials
    Drug Delivery & Materials
    • Drug Delivery & Materials
    • GMP Drug Delivery Manufacturing
    • cGMP Medical Polymer Synthesis
  • Products
  • Seqens Group
  • Careers
  • Newsroom
  • Contact
  • Seqens Group
  • Careers
  • Newsroom
  • Contact
Our locations
  • Custom development & Manufacturing
    Custom development & Manufacturing
    • Early Phase API Development
    • Late Phase API Development
    • Custom API manufacturing Services
    • Special Technologies & Capabilities
      • Reactions Technologies
      • Controlled Substance API Manufacturing
      • Biocatalysis Contact Manufacturing
      • High-Potency APIs (HPAPIs)
    • SEQENS' LAB
      • About Seqens'Lab
      • Seqens’Lab 360° TOUR
  • Proprietary APIs
    Proprietary APIs
    • APIs Development & Production
    • APIs Solid-Form Customization
    • Drug substance Regulatory Affairs and Quality Assurance
    • Product Catalog
  • Consumer Health APIs
  • Proprietary API Intermediates
    Proprietary API Intermediates
    • Registered API Intermediates & Raw Materials
    • Pre-GMP API Intermediates / Catalog
  • Drug Delivery & Materials
    Drug Delivery & Materials
    • GMP Drug Delivery Manufacturing
    • cGMP Medical Polymer Synthesis
  • Products
Top of page
Share

Newsroom

Home Newsroom
Articles

Phasing forward with Seqens

09th may 2019

Three custom development and manufacturing organizations – PCAS S.A. in France, Chemie Uetikon in Germany and PCI Synthesis in the United States –…

Read more
General / Research and Development 07th may 2020

Flow chemistry for efficient and safe synthesis of APIs and intermediates

DOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…

Read more
API Manufacturing / General 24th february 2020

API lifecycle management: A CDMO perspective

Didier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…

Read more
API Manufacturing / General 06th february 2020

Developing Controlled Substances Requires a Whole New Level of Global Diligence

4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…

Read more
API Manufacturing / Articles / General 31st january 2020

The Growth of the Generic Drug Marketplace

The Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…

Read more
API Manufacturing / Articles / General / Research and Development 29th november 2019

Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs

Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.

Read more
API Manufacturing 28th october 2019

Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated…

Read more
General 23rd november 2020

SEQENS is committed to the development and production of critical molecules in France

SEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate…

Read more
API Manufacturing / General 14th october 2020

A new large scale potent API manufacturing unit at SEQENS Villeneuve-La-Garenne

Shifting needs in the pharmaceutical market are driving a stronger demand for specialized production units to manufacture highly potent active…

Read more
General 03rd august 2020

Lahr’s Site: a Seqens CDMO plant.

Founded in 1991, The site of Lahr is part of SEQENS CDMO since mid-2015. The site is specialized in the development and manufacturing…

Read more
API Manufacturing / Articles / Press Releases / Research and Development 28th may 2020

What kind of chemical structure will help the control of the most life-threatening side effects associated with CoVid-19- Some Salicylamide derivatives appears to be able to compete

DOWNLOAD THE PRESS RELEASE Gérard Guillamot SEQENS Scientific Director Due to the urgency of finding a treatment against CoVid-19,…

Read more
API Manufacturing / General 18th may 2020

New warehouse for active ingredients (API’s) in Lahr

A new warehouse for active ingredients The production of active ingredients on site Lahr has increased steadily over the last years. It was…

Read more
API Manufacturing / Articles / General 19th february 2020

The CDMO’s Challenges Developing An Oral Suspension For Children

By, Didier Combis, Commercial Director, Seqens CDMO; Christine Adam, Business Development Manager, Unither Pharmaceuticals and Jean Francois Cordoliani, Site Director, Unither Développement Bordeaux…

Read more
General 18th february 2020

Why sponsors are turning to Western sources for regulatory starting materials (RSMs)

By Don LaFerle, Senior Vice President, Custom Synthesis, Seqens CDMO The ICH Q7 defines RSMs (Regulatory Starting Materials) as the point at…

Read more
API Manufacturing / General 10th february 2020

Potent project

The Villeneuve-la-Garenne plant continues its transformation through the Potent project, which will enable the group to access the production of active pharmaceutical ingredients…

Read more

Join the seqens teams !

See our job offers

Subscribe to our newsletter

  • Home
  • Newsroom
  • Privacy policy
  • GTC

About SEQENS

Contact us

Contact us

Follow the seqens evolution on

social media

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.

Manage my cookies preferences

Some of the features of this site (content sharing on social networks, live video playback) are based on services provided by third-party sites. These functions store cookies that allow these sites to track your browsing. These cookies are only stored if you give your consent. You can inquire about the nature of the cookies placed, accept or reject them either globally for the entire site and all services, or service by service.

Required cookies

Cookies d'analyse d'audience

Cookies related to social networks

Save
Ok

DISCOVER OUR NEWS

Learn more